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Background: In clinical trials in childhood asthma, outcomes reflecting short-term disease activity are frequently
measured, whilst functional status, quality of life (QoL), and long-term treatment effects are rarely assessed. There is
also non-uniformity across studies in the selection and measurement of outcomes within these domains. The
development of a core outcome set has the potential to reduce heterogeneity between trials, lead to research that
is more likely to have measured relevant outcomes, and enhance the value of evidence synthesis by reducing the
risk of outcome reporting bias and ensuring that all trials contribute usable information.
Methods: Paediatricians and specialist nurses, identified through the British Paediatric Respiratory Society,
completed a two-round Delphi survey. Separate cohorts of parents of children younger than 18 years, recruited in
clinics, participated in each round. Young people with asthma, aged at least 13 years, participated in the first round.
Outcomes were identified separately for preschool and school-aged children.
We identified outcomes considered important in routine clinical assessment by clinicians and parents/young
people. In round 1, 46 clinicians suggested outcomes they considered important when deciding whether to adjust
a child’s asthma therapy regime, and 49 parents/young people were asked, using open questions, how they judged
whether their child’s (for young people, their own) asthma therapy was appropriate. Two researchers independently
classified responses into appropriate, corresponding outcomes.
In round 2, 43 clinicians and 50 parents scored, from 0–4, the importance of each outcome suggested by at least
10 % of round 1 responders and selected the three most important.
Results: The most important outcomes, when making shared decisions about regular therapies for school-aged
and preschool children with asthma, were daytime and nocturnal symptoms, exacerbations, QoL, and mortality.
Results from parents and clinicians were generally concordant, but parents placed more emphasis on long-term
treatment effects.
Conclusions: We have developed a methodology to identify outcomes of most relevance to clinicians, parents,
and young people when evaluating regularly administered therapies for asthma. Daytime and nocturnal symptoms,
exacerbations, QoL, and mortality are particularly important outcomes that should be measured and reported in all
clinical trials of regular therapies for children with asthma.
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To inform clinical practice, clinical trials that aim to de-
termine benefits and risks of treatments should measure
outcomes that are important to patients, and useful to
clinicians and policymakers. It can be difficult, however,
for trialists to know which outcomes are most important
for a given condition. Chronic illnesses can affect the
lives of patients and families in a variety of ways, each of
which can potentially be improved by an intervention
and could therefore be measured as an outcome.
In a systematic review, of studies that aimed to deter-
mine which outcomes to measure in clinical trials in
children [1], we found only one study relating to asthma
[2]. In this study, 14 clinicians and researchers indicated,
by questionnaire, which outcomes they felt were most
appropriate for a variety of clinical, public health, and re-
search settings related to asthma. More recently, the
American Thoracic Society (ATS) and European Re-
spiratory Society (ERS) held workshops, attended by 24
clinical researchers, with the aim of recommending
which outcomes to select in clinical trials of regular
therapies for asthma and how these could be measured
in a standardised manner [3]. These recommendations
relate to adults and adolescents, but the authors suggest
that, with some special considerations, the outcomes
could also be relevant for children older than 6 years.
In another systematic review, we aimed to identify
which outcomes and domains were measured in rando-
mised controlled trials (RCTs) of inhaled corticosteroids
for children with asthma [4]. We found that studies al-
most always measure clinical and physiological markers
of short-term disease activity, but quality of life (QoL),
functional status, and long-term outcomes are rarely
assessed. We also noted marked inconsistency between
studies in the way that particular outcomes are mea-
sured and reported, and non-uniformity in the defini-
tions of clinical events, especially exacerbations, used as
endpoints.
We recommended that one solution to these problems
would be to agree on a minimum set of core outcomes
that should be measured and reported in all RCTs that as-
sess the effectiveness of treatments given to prevent symp-
toms and complications in children with asthma. Core
outcome sets increase the likelihood that important out-
comes will be measured, improve evidence synthesis by
reducing heterogeneity between studies, and reduce
outcome-reporting bias [5]. Such core outcome sets have
been implemented in other conditions, notably in the field
of rheumatology. The OMERACT (Outcome Measures in
Rheumatology) collaboration has designed core outcome
sets for various conditions by reaching consensus amongst
clinicians and researchers about which outcomes to meas-
ure [6], and more recently by asking patients which out-
comes they feel are most important [7]. The COMET(Core Outcome Measures in Effectiveness Trials) Initiative
brings together researchers interested in the development
and application of core outcome sets [8]. Data on over
120 published or on-going studies related to core outcome
set development have been entered into the COMET re-
pository (http://www.comet-initiative.org.). The outcomes
measured in clinical trials, in order to evaluate whether
the benefits of a treatment outweigh its harms, should be
aligned to the assessments that are used in clinical prac-
tice to decide whether a treatment regime is satisfactory.
Core outcome sets do not need to comprise an extensive
list of outcomes, but rather a few particularly important
ones that reflect the ways in which patients, families, and
clinicians assess whether a treatment regime is satisfac-
tory, and make shared decisions about whether to con-
tinue or modify it. There is little guidance, however, for
researchers who wish to involve these groups in the devel-
opment of a core outcome set.
The aim of this study, therefore, was to develop and
pilot a method by which to identify outcomes of particular
relevance when evaluating the effects of regular therapies
for chronic childhood asthma, from the perspective of
clinicians involved in the out-patient management of chil-
dren with asthma, parents of children younger than
18 years, and young people aged between 13 and 18 years.
In previous attempts to develop core outcomes sets, parti-
cipants have generally considered outcomes that had
already been measured in clinical trials [8,9]. This ap-
proach may overlook important outcomes if they have not
previously been routinely measured and perpetuate the in-
clusion of others, which may be less relevant. We there-
fore took an empirical approach of focusing on aspects of
a child’s symptoms or history that would lead to a conclu-
sion by a clinician, parent, or young person that treatment
was either adequate or not.
Methods
Ethics statement
We asked the advice of the National Research Ethics
Service (NRES) about whether this study required ethical
review by an NHS Research Ethics Committee, and they
advised that this should be considered as service evalu-
ation and development. No identifiable details about
patients or families were collected. To acknowledge the
clinicians who participated in the study, we have listed
them, having obtained consent individually to do so, in
Additional file 1.
This study was conducted, using questionnaires, in two
phases (1 and 2). The purpose of phase 1 was to identify a
long list of potential outcomes, and phase 2 was designed
to identify which of these were most important. Partici-
pants were asked to consider outcomes for evaluating
therapies taken regularly rather than for acute exacerba-
tions. Outcomes for preschool (younger than 5 years) and
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considered separately. This was because not all outcomes
can be measured in younger children, and different out-
comes may have varying relevance at different ages. For
example, physiological tests of lung function are rarely
measured in preschool children because of technical diffi-
culties, and functional status may be assessed in different
ways because the pattern of normal daily activities changes
when children start school.
To ascertain the views of clinicians, all members of
the British Paediatric Respiratory Society (BPRS) and a
network of asthma nurses were invited to participate
in a two-round, web-based, anonymised Delphi survey.
The Delphi technique, which has been used to develop
other core outcome sets [9], is a structured method
for reaching consensus, in which participants complete
sequential rounds of questionnaires, with the results of
each questionnaire informing the composition of the
next. The BPRS comprises medical and non-medical
professionals within the UK who care for children with
respiratory problems. To be eligible to participate, we
invited clinicians and nurses who had current experi-
ence of managing children with asthma, but not ne-
cessarily experience of designing or conducting clinical
trials. The selection of participants on the basis of
relevant clinical experience, rather than research ex-
pertise, differs from the approach generally taken when
core outcome sets have been developed.
Parents were invited to complete paper-based surveys in
asthma clinics in Alder Hey Children’s Hospital (AHCH),
a large paediatric hospital in the North of England, where
patients are referred from primary and secondary care.
Parents of all children younger than 18 years who were
prescribed regular preventer therapy for asthma and did
not have respiratory co-morbidities were eligible. Young
people aged 13 to 18 who attended these clinics were also
invited, because we anticipated that they might have dif-
ferent goals for their asthma treatment. The lower age
limit was based on clinical experience that teenagers are
generally more able to discuss their asthma than younger
children. When participants were approached in the out-
patient department, one reviewer (IS) explained verbally
what was meant by the terms clinical trials and outcomes,
and why we were conducting the study. We elected to use
questionnaires rather than focus groups to minimise the
burden on participants and to enable the involvement of a
larger sample. We also felt that participants’ opinions did
not require in-depth analysis, which would have been best
answered using qualitative research techniques.
Phase 1
Phase 1 comprised the first round of the Delphi survey
of clinicians, and a survey of parents and young people.
Open questions were asked in order to identify a longlist of outcomes that could be relevant to clinic consulta-
tions. In a pilot phase, we asked parents and young
people with asthma, and a group of young people with
experience of reading clinical trial information leaflets
whether the questions were easy to understand and ap-
propriate; the questions were then refined accordingly
with extensive input from parents and young people.
The questions included in the questionnaires are listed
in Table 1.
IS interpreted each response from clinicians, parents,
and young people, and decided which outcome of treat-
ment was being described. The broad framework for
classifying responses as outcomes was based on the
domains, subdomains, and outcomes identified in the
systematic review described earlier [4]. This comprised
the following six categories:
 Short-term disease activity: Symptoms; relief inhaler
use; exacerbations; lung function; overall asthma
control
 Physical consequences of disease: death; progression
of asthma into later childhood or adulthood
 Functional status: ability to exercise or play sport;
activities of daily living; school attendance
 Family outcomes and Quality of Life: overall QoL;
emotional well-being; family outcomes
 Adverse effects of therapy: short-term adverse
effects; long-term adverse effects
 Health resource utilisation
Four reviewers (IS, RG, PRW, RLS) discussed whether
each of the responses that did not fit into this classifica-
tion should constitute a ‘new’ outcome.
In order to identify responses that were open to inter-
pretation and to make categorisation of responses more
accurate, reviewer 2 (RG) independently categorised the
first 36 (72 %) questionnaires received from parents and
young people, and reviewer 3 (PRW) independently ana-
lysed a randomly selected sample of 9/46 (20 %) of the
questionnaires completed by clinicians. Disagreements
were discussed among all four reviewers. Further review
of the responses from parents and young people was not
deemed necessary because interpretation of responses
became easier and agreement became greater as the
study progressed. The responses from clinicians were
easier to interpret and categorise, and agreement among
reviewers was excellent, so further review of these ques-
tionnaires was not deemed necessary.
To enable each group of participants, regardless of its
size, to have equal opportunity to suggest outcomes for
phase 2, those outcomes suggested by at least 10 % of
young people and/or parents and/or clinicians were car-
ried forward to the next phase. By censoring in this way,
we reduced the number of outcomes listed on the phase
Table 1 Questions asked in the phase 1 questionnaires
distributed to clinicians, parents, and young people
Clinician questionnaire “When you see children with asthma in clinic,
you make an assessment as to whether their
treatment is working. Please list up to five
beneficial or harmful outcomes of treatment
that you find clinically most important in
school-aged/preschool children. These factors
should be things that you consider, when
deciding whether to recommend continuing
on current treatment or altering a child’s
regular asthma therapy regime”
Parents (young peoples’)
questionnaire
“Over the last 12 months, have you generally
felt that the regular preventer treatment that
your child (you) takes has kept their asthma
under control? Yes/No. If you ticked YES,
please tell us what aspects of your child’s
(your) asthma, or their daily life, have made
you feel happy that they are on the correct
regular medication. If you ticked NO, please
leave this question blank”
“Over the last 12 months, have there been
times when you felt that your child’s (your)
regular preventer treatment should be
increased or changed, because their (your)
asthma was not under control? Yes/No. If you
ticked YES, please tell us the reasons why you
were not satisfied with the regular preventer
treatment that they (you) were taking? If you
ticked NO, please leave this space blank”
“Does anything worry you about the fact that
your child (you) has asthma? Yes/No. If you
ticked YES, please tell us the worries you have
about the fact your child (you) has asthma. If
you ticked NO, please leave this space blank”
“Does anything worry you about the regular
preventer treatment that your child (you) takes
for their asthma? Yes/No. If you ticked YES,
please tell us what worries you have about the
treatment your child takes for their asthma.
Please be as specific as you can. If you ticked
NO, please leave this question blank”
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tially genuine importance. The reviewers discussed the
individual outcomes that had not been suggested by suffi-
cient numbers of participants, but were measured in at
least 10 % of RCTs identified in the systematic review
described earlier [4]. If nearly 10 % of both clinicians and
parents suggested the outcome, it was carried forward to
the next phase, because we felt that, if we had a larger
sample size, the outcome may have been suggested by
sufficient numbers of participants.
The study flowchart is shown in Figure 1. At the start of
the study, 260 members of the BPRS and 21 specialist
asthma nurses were invited to participate. Of the 46
respondents, who came from both district general hospitals
and tertiary respiratory centres, 38 were paediatricians (of
whom 16 were specialist respiratory paediatricians, 16 were
general paediatricians, and 6 were clinical academics), and8 were respiratory nurses. The participants are listed in
Additional file 1. In total, 38 parents (of whom 27 attended
with school-aged children and 11 attended with preschool
children) and 11 young people, ranging from 13 to 15 years,
participated in phase 1.
Phase 2
Only the clinicians who participated in phase 1 were
invited to complete the phase 2 questionnaire. We
assumed that if clinicians did not respond to phase 1,
they would be unwilling or unable to participate in
phase 2, so we took the pragmatic decision not to con-
tact them again at this stage. Parents attending asthma
clinics at AHCH were invited to participate, employing
the same eligibility criteria as those used in phase 1. We
felt confident in running a Delphi process with clini-
cians, but felt that questionnaires to parents should be
delivered in person, so that the questions could be
explained. The advantages of doing so would be that the
questions would be better understood, and the response
rate to the phase 2 questionnaire would be higher. We
decided to use a new cohort for the second round of the
study so that parents involved in phase 1 would not
need to be contacted outside their clinic appointment.
We felt that two cohorts would be sufficiently similar to
enable this approach because phases 1 and 2 were con-
ducted in identical clinics, so we assumed that family
demographics and the severity of the children’s asthma,
were comparable across the two phases of the study.
When parents were invited to participate, the recruiting
researcher (IS) explained the purpose of the study and the
use of the term ‘outcome’ verbally. To increase numbers,
parents of preschool children were recruited at a local dis-
trict general hospital, whose paediatric respiratory depart-
ment treats children with asthma with broadly similar
characteristics to those seen at AHCH. As it was unclear
whether young people would be able to answer the ques-
tionnaire in phase 2, they were not included. Unlike ques-
tions asked in phase 1, those questions asked in phase 2
did not reflect actual discussions that take place with
young people in clinic consultations. We felt that in order
to involve young people in phase 2, the questionnaires
would need to be rigorously validated in this population,
and this would be outside the scope of the study. In an-
other attempt to increase the size of the sample, the phase
2 questionnaire was distributed by Asthma UK, the largest
UK-based asthma charity, to parents of children with
asthma, who had previously expressed an interest in being
involved in clinical research.
The questionnaires distributed to parents and clinicians
in phase 2 are included in Additional file 2. To identify the
relative importance of each outcome, participants were
asked the following question: “Regular treatments for chil-
dren can have a variety of beneficial effects, each of which
Figure 1 Study flowchart showing participants in each phase of the study.
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score how important each of the following outcomes are
on a scale of 0–4”. They were also asked to pick the three
outcomes they felt were most important. In order to en-
sure that important outcomes were not missed, partici-
pants were asked to suggest any unlisted outcomes that
they would have selected in their top 3.
The results from clinicians and parents were ana-
lysed separately, and those of parents of preschool
children were analysed separately from those of par-
ents of school-aged children. Each outcome was
ranked in terms of the proportion of participants who
selected it in their top 3.
Phase 2 was completed by 43 clinicians and 50 parents
(of whom 27 attended with school-aged children and 23
attended with preschool children). In spite of several
reminders, only 13/118 (11 %) responses were received
from Asthma UK. As a result, these data have not been
included in our analyses.Results
Identification of outcomes in phase 1
The results of phase 1 are shown in Additional file 3.
Participants suggested a total of 29 outcomes, of which
symptoms, and their effect on ability to exercise and lead
a normal life, exacerbations, and adverse effects of ther-
apy were most frequently suggested. One outcome
(QoL) was carried forward to the phase 2 questionnaire
for preschool children despite not being suggested by
10 % of any group of participants, because it was sug-
gested by 9 % of both parents and clinicians.
There was good agreement among reviewers with
regards to how most responses should be categorised,
according to the framework of outcomes described earl-
ier. Responses relating to long-term outcomes, however,
were more difficult to categorise, because it was often
unclear whether participants referred to future risk of
asthma, other respiratory illness, general health pro-
blems, or effects on activities of daily living, and we were
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hood. We felt it would be appropriate to combine these
responses into the outcome ‘health-related problems
when older’. A summary of the agreement among
reviewers is shown in Additional file 4.
Ranking of outcomes in phase 2
All the outcomes listed in the phase 2 questionnaire
were considered important. By asking participants to se-
lect their top 3, we were able to identify those of particu-
lar importance.
The results for each outcome listed in the phase 2
questionnaire relating to preschool children are shown
in Table 2. The most important outcomes for clinicians
and parents were symptoms, especially those arising at
nighttime, exacerbations, QoL, mortality, and hospital
admission. The results for each outcome listed in the
phase 2 questionnaire relating to school-aged children
are shown in Table 3. The most important outcomes in
this age group were symptoms, exacerbations, QoL, abil-
ity to perform normal activities, and mortality.
Parents and clinicians generally agreed on which out-
comes were most important. However, parents, of both
preschool and school-aged children, scored long-term
outcomes more highly than did clinicians. Both parents
and clinicians considered long-term adverse effects of
therapy more important than short-term adverse effects.Table 2 Preschool children: the importance of each outcome
clinicians and parents
Clinicians
(n=43)
Outcome Clinician rank Median
(IQR)
Nu
o
Nocturnal symptoms 1 4 (3, 4)
Exacerbations 2 4 (3, 4)
Quality of life 3 3 (3, 4)
Daytime symptoms 4 4 (3, 4)
Death 5 4 (2, 4)
Hospital admission 6 4 (3, 4)
Parent/child global assessment
of control
7 4 (3, 4)
Impact of asthma on the family 8 4 (3, 4)
Use of reliever 9 3 (3, 4)
Normal activities 10 4 (3, 4)
Long-term AE 11 4 (3, 4)
School attendance 12 3 (3, 4)
Activity or exercise 13 3 (3, 4)
GP/A+ E attendance 14 4 (3, 4)
Growth 15 3 (3, 4)
Health-related problems when older 16 3 (2, 4)
Short-term AE 17 3 (2, 3)Discussion
Main findings
We found that the outcomes considered most important
in childhood asthma by clinicians, patients, and parents
were symptoms, exacerbations, quality of life, and mor-
tality. We identified these by asking clinicians, parents,
and young people, what outcomes they reviewed or
reported during routine clinical consultations to enable
them to decide, jointly, whether or not therapy should
be continued, augmented, or reduced. This differs from
the approach generally taken in deciding outcomes for
clinical trials, which is to focus on what has been mea-
sured before [9]. In this pilot study, we have shown that
it is feasible, and useful, to involve clinicians, patients,
and families, in identifying which outcomes are import-
ant when making shared decisions about management in
clinical practice.
The frequency and severity of symptoms and exacer-
bations are important for clinicians and trialists in decid-
ing whether asthma is well controlled [10], so it is
unsurprising that they emerged as important compo-
nents of a core outcome set in this area. Although lung
function is frequently assessed in asthma clinical trials
because it is an objective evaluation of efficacy, we found
that parents and clinicians place much more emphasis
on clinical measures of asthma control when assessing
the effectiveness of therapy.listed in the phase 2 questionnaire, as scored by
Parents
(n=23)
mber (%) scoring
utcome in top 3
Parent rank Median
(IQR)
Number (%) scoring
outcome in top 3
19 (44) 1= 4 (4, 4) 10 (43)
15 (35) 3 4 (4, 4) 7 (30)
13 (30) 4 4 (3, 4) 5 (22)
11 (26) 10 4 (3, 4) 3 (13)
10 (23) 1= 4 (4, 4) 10 (43)
9 (21) 7 4 (4, 4) 4 (17)
9 (21) 11 4 (3, 4) 3 (13)
8 (19) 16 4 (3, 4) 1 (4)
8 (19) 8 4 (3, 4) 4 (17)
5 (12) 14 4 (3, 4) 2 (9)
7 (16) 13 4 (4, 4) 2 (9)
5 (12) 6 4 (3, 4) 5 (22)
4 (9) 12 3 (2, 4) 3 (13)
4 (9) 15 4 (3, 4) 2 (9)
3 (7) 9 4 (3, 4) 3 (13)
0 5 4 (4, 4) 5 (22)
0 17 3 (3, 4) 0
Table 3 School-age children: The importance of each outcome listed in the phase 2 questionnaire, as scored by
clinicians and parents
Clinicians
(n=43)
Parents
(n=27)
Outcome Rank (n/17) Median
(IQR)
Number (%) scoring
outcome in top 3
Rank Median
(IQR)
Number (%) scoring
outcome in top 3
Quality of Life 1 4 (3, 4) 20 (47) 2 4 (4, 4) 9 (33)
Exacerbations 2 4 (4, 4) 18 (42) 3 4 (4, 4) 9 (33)
Nocturnal symptoms 3 4 (4, 4) 16 (37) 4 4 (4, 4) 8 (30)
Normal activities 4 4 (4, 4) 12 (28) 8= 4 (4, 4) 4 (15)
Daytime symptoms 5 4 (4, 4) 11 (26) 6 4 (4, 4) 6 (22)
Death 6 4 (2, 4) 11 (26) 1 4 (4, 4) 14 (52)
Use of reliever inhaler 7 4 (3, 4) 9 (21) 10 4 (3, 4) 3 (11)
Hospital admission 8 4 (3, 4) 8 (19) 12 4 (4, 4) 2 (7)
Activity or exercise 9 4 (3, 4) 7 (16) 5 4 (3, 4) 7 (26)
Long-term adverse effect 10 4 (4, 4) 7 (16) 8= 4 (4.4) 4 (15)
School attendance 11 4 (3, 4) 7 (16) 11 4 (4, 4) 2 (7)
Parent/child global assessment
of control
12 4 (3, 4) 7 (16) 14 4 (3, 4) 2 (7)
Lung function tests 13 3 (2, 3) 5 (12) 15 4 (3, 4) 1 (4)
GP/A+ E attendance 14 4 (3, 4) 3 (7) 16 4 (3, 4) 0
Growth 15 4 (3, 4) 2 (5) 13 4 (3, 4) 2 (7)
Health-related problems when older 16 3 (2, 4) 0 7 4 (4, 4) 5 (19)
Short-term adverse effect 17 3 (2, 3) 0 17 4 (3, 4) 0
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ventions on measures of functional status, such as the
ability to perform normal activities, play sports, and at-
tend school, and also on overall QoL, were fundamental
to the assessment of their benefit. Clinical markers of
disease, which do not evaluate psychosocial and func-
tional effects of having asthma [10], should not be used
as substitutes for such assessments [11]. Although QoL
outcomes are assessed relatively infrequently in clinical
trials in asthma [4], we recommend that they be
included in a core outcome set, either as individual com-
ponents of functional status or emotional well-being, or
as part of a validated composite outcome.
We found that parents place more emphasis on long-
term beneficial effects of therapy than clinicians do. Previ-
ous qualitative research has identified that many parents
of children with asthma worry about long-term effects on
health [12], and cohort studies suggest that children with
asthma are likely to continue to have asthma as adults
[13]. Long-term harmful effects of therapies were import-
ant to both clinicians and parents in our study. These have
also been shown to be a major concern for parents and
children [14], and are an important research priority [15].
We feel that, despite difficulties of measuring long-term
effects of therapies, they should be also be part of a core
outcome set, although further work is needed to identifythe most appropriate ways to measure and report these
outcomes. Around half of the parents who participated in
phase 2 selected ‘prevention of death’ as one of their top
three outcomes, compared with a quarter of clinicians.
One reason for this discrepancy may be that clinicians
may feel that because death from asthma in childhood is
very rare, it should not be part of a core outcome set.
We recommend, however, that death should always be
reported as a secondary outcome in clinical trials in chil-
dren with asthma.
Comparison with the ATS/ERS outcomes taskforce
As mentioned earlier, a recent ATS/ERS taskforce [3] has
recommended outcomes that should be measured in
clinical trials of regular therapies in asthma. Outcomes
measured in clinical trials were identified by a literature
review. Working groups comprising clinicians, research-
ers, and pharmaceutical industry representatives, reached
consensus using round-table open discussions about the
suitability of these outcomes for evaluating current and
future asthma-related problems. Two paediatricians
assessed whether the recommendations were applicable
to clinical trials in children.
The recommended outcomes, which were symptoms,
use of reliever inhaler, composite scores for assessing
asthma control, exacerbations, quality of life, pre- and
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tion decline), and adverse effects of therapy, are compar-
able with our results. The main difference was that
participants in our study considered physiological mea-
sures of lung function, although ‘essential’ outcomes in
the ATS/ERS core set, one of the least important out-
comes. Other groups have also highlighted issues relat-
ing to whether or not outcomes measured in clinical
trials in adults are applicable to children [16]. The dis-
crepancy may also reflect our empirical approach of con-
sidering the importance of outcomes in the context of
factors that affect decisions in a clinic consultation com-
pared to the ATS/ERS approach of starting with what
has been measured previously and assessing the rele-
vance of those outcomes. We acknowledge that FEV1
will continue to be measured in clinical trials in asthma,
because it is reliable and repeatable, but our work high-
lights that other outcomes are of more importance when
making clinical decisions.Limitations of this study
Our sample focussed on children whose asthma is mana-
ged by hospital paediatricians, although much asthma is
treated in primary care. The study should be replicated
amongst primary care doctors, practice nurses, parents
with children whose asthma is managed in primary care,
and young people who are treated in this setting. This
will also address the fact that only small numbers of
young people were included in our study in phase 1. We
feel, however, that our results are relevant to a high pro-
portion of clinical trials, which are usually conducted in
the hospital setting [17-19]. We have also sampled parti-
cipants from the UK, and it is possible that if this study
were replicated in other countries, some other outcomes
may have been found to be of particular importance. For
this reason, we feel that future work to develop a more
definitive core outcome set for childhood asthma, which
is broadly applicable internationally, should incorporate
the views of participants from several countries.
Despite good agreement among reviewers, certain
responses in phase 1 were open to interpretation. One ex-
ample related to the description of symptoms. Although
some parents specified daytime or nocturnal symptoms,
others did not. A pragmatic decision was taken that a de-
scription of symptoms should be classified as referring to
nocturnal symptoms only if the response was this specific.
If our assumption had been false, the number of partici-
pants suggesting ‘night-ime symptoms’ could have been
underestimated in phase 1, or those suggesting ‘daytime
symptoms’ could have been overestimated. Ultimately, our
results appear to be robust to this decision, because noc-
turnal symptoms were included in the phase 2 question-
naire, and daytime symptoms scored highly.Responses from parents in phase 1 that were classified
as representing QoL were also open to interpretation.
However, even if we had misinterpreted some responses
from parents, in phase 1, this is unlikely to have affected
the phase 2 questionnaire. We kept a broad definition of
QoL that reflects a patient’s overall well-being, including
psychosocial status. A detailed examination of what parti-
cipants meant by QoL was outside the scope of this study.
Our sample of clinicians represented only 18 % of
people to whom the invitation was sent, although our
sample size is comparable to other studies that have
attempted to determine which outcomes to measure in
clinical trials [9]. It is possible that this may have
resulted in bias towards participants with specific inter-
est in this type of study. Although we cannot be certain
about the views of the 214 non-responders, we see no
reason why this group should differ from those who did
respond. We assumed that these clinicians did not want
to be involved in the study, or were too busy, so we felt
it would be inappropriate to send them an email inviting
them to phase 2.
Conclusions
In this study, we have developed and piloted a method for
involving patients, parents, and clinicians in the process of
identifying relevant outcomes for clinical trials. The repli-
cation of this study in other settings will be important for
the development of a core outcome set for childhood
asthma. We recommend that others adopt this broad em-
pirical approach of attempting to align outcomes for
assessing interventions in clinical trials with those that are
used for making decisions in clinical practice.
When making shared clinical decisions about daily
management of childhood asthma, parents and clinicians
wish to know whether an intervention controls symp-
toms, prevents morbidity and mortality associated with
exacerbations, and improves QoL. Outcomes in clinical
trials, which generally measure short-term clinical and
physiological efficacy, may not be sufficient to fully
evaluate the effects of interventions that are meaningful
in clinical practice.
A core outcome set for childhood asthma that not only
suits the needs of researchers, but also improves the use-
fulness of clinical trials from the perspective of clinicians,
parents, and policy-makers can be based on our findings
in conjunction with the recommendations of the recent
ATS/ERS taskforce. Agreement amongst a wider group
of people involved in such trials should focus on identify-
ing the best ways to measure symptoms and the effects
of asthma on daily life. Standardising the definitions of
endpoints, especially exacerbations, would also reduce
heterogeneity between studies. Further discussion should
also address the role of physiological measures of lung
function in clinical trials in children with asthma, and
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harmful effects of treatments should be measured in all
such trials.
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